Itraconazole

Axita is used for the treatment of oropharyngeal candidiasis, vulvovaginal candidiasis, pityriasis versicolor, tinea pedis, tinea cruris, tinea corporis, tinea manuum, onychomycosis, histoplasmosis. It is indicated in the treatment of systemic candidiasis, aspergillosis, and cryptococcosis (including
... Read more
Axita is used for the treatment of oropharyngeal candidiasis, vulvovaginal candidiasis, pityriasis versicolor, tinea pedis, tinea cruris, tinea corporis, tinea manuum, onychomycosis, histoplasmosis. It is indicated in the treatment of systemic candidiasis, aspergillosis, and cryptococcosis (including cryptococcal meningitis). It is also used for maintenance therapy in AIDS patients to prevent relapse of underlying fungal infections and in the prevention of fungal infection during prolonged neutropenia.

Dosage & Administration

100 & 200 mg preparation
:
For non-systemic fungal disease-
Vulvovaginal candidiasis
: 200 mg twice daily for 01 day
Pityriasis versicolor
: 200 mg once daily for 07 days
Tinea corporis, tinea cruris
: 100 mg once daily for 15 days or 200 mg once daily for 7 days
Tinea pedis, tinea manuum
: 100 mg once daily for 30 days
Oropharyngeal candidiasis
: 100 mg once daily for 15 days, Increase dose to 200 mg once daily for 15 days in AIDS or neutropenic patients because of impaired absorption in these groups.
Onychomycosis
(toenails with or without fingernail involvement): Either 200 mg daily for 3 months or course (pulse) of 200 mg twice daily for 7 days, subsequent courses repeated after 21 days' interval. Fingernails two courses, toenails three courses.
For systemic fungal disease-
Aspergillosis
: 200 mg once daily for 2-5 months Increase dose to 200 mg twice daily in case of invasive or disseminated disease
Candidiasis
: 100-200 mg once daily for 3 weeks-7 months. Increase dose to 200 mg twice daily in case of invasive or disseminated disease
Non-meningeal Cryptococcosis
: 200 mg once daily for 10 weeks
Cryptococcal meningitis
: 200 mg twice daily for 2-6 months
Histoplasmosis
: 200 mg once daily twice daily for 8 months
Maintenance in AIDS
: 200 mg once daily until immune recovery
Prophylaxis in neutropenia
: 200 mg once daily until immune recovery
The dose and duration of treatment for systemic antifungal disease should be adjusted depending on the clinical response.
65 mg & 130 mg preparation
:
For non-systemic fungal disease-
Vulvovaginal candidiasis
: 130 mg twice daily for 1 day
Pityriasis versicolor
: 65 mg twice daily for 7 days
Tinea corporis and tinea cruris
: 65 mg daily for 15 days OR 65 mg twice daily for 7 days
Tinea pedis and tinea manuum
: 65 mg once daily for 30 days
Oropharyngeal Candidiasis
: 65 mg once daily for 15 days, increase dose to 65 mg twice daily for 15 days in AIDS or neutropenic patients because of impaired absorption in these groups.
Onychomycosis
(toenails with or without fingernail involvement): Either 65 mg twice daily for 3 months or course (pulse) of 130 mg twice daily for 7 days, subsequent courses repeated after 21 days interval. Fingernails two courses, toenails three courses.
For systemic fungal disease-
Aspergillosis
: 65 mg twice daily for 2-5 months.Increase dose to 130 mg twice daily in case of invasive or disseminated disease
Candidiasis
: 65-130 mg once daily for 3 weeks-7 months. Increase dose to 65 mg twice daily in case of invasive or disseminated disease
Non-meningeal Cryptococcosis
: 65 mg twice daily for 10 weeks
Cryptococcal meningitis
: 130 mg twice daily for 2-6 months
Histoplasmosis
: 130 mg once daily-twice daily for 8 months
Maintenance in AIDS
: 65 mg twice daily until immune recovery
Prophylaxis in neutropenia
: 65 mg twice daily until immune recovery
The dose and duration of treatment for systemic anti-fungal disease should be adjusted depending on the clinical response.
50 mg capsule
-
For non-systemic fungal disease:
Indication
Dose & Duration
Pityriasis versicolor
Treatment doses
:
Children >4 weeks to <12 years old:
Usual dose: 1.25-2 mg/kg/dose (to a maximum initial dose of 100 mg) given twice daily. Dose should be adjusted based on therapeutic drug monitoring.
The dose may be increased to 5 mg/kg/dose (to a maximum initial dose of 100 mg) given twice daily for severe infections. The maximum daily dose may be increased based on therapeutic drug monitoring in discussion with the physicians.
The dose should be rounded to the nearest 50 mg to facilitate administration.
Children ≥12 years old: Usual dose: 50 mg to 100 mg once daily. Dose may be increased to 100 mg twice daily in severe infections.
Prophylaxis doses
:
Children ≥2 years old: 2.5 mg/kg/dose given once daily (to a maximum initial dose of 200 mg daily). Dose should be adjusted based on therapeutic drug monitoring.
Tinea corporis and tinea cruris
Tinea pedis and tinea manuum
Oropharyngeal Candidiasis
Onychomycosis (toenails with or without fingernail involvement)
For systemic fungal disease:
Indication
Dose & Duration
Aspergillosis
Treatment doses
:
Children >4 weeks to <12 years old:
Usual dose: 1.25-2 mg/kg/dose (to a maximum initial dose of 100 mg) given twice daily. Dose should be adjusted based on therapeutic drug monitoring.
The dose may be increased to 5 mg/kg/dose (to a maximum initial dose of 100 mg) given twice daily for severe infections. The maximum daily dose may be increased based on therapeutic drug monitoring in discussion with the physicians.
The dose should be rounded to the nearest 50 mg to facilitate administration.
Children ≥12 years old: Usual dose: 50 mg to 100 mg once daily. Dose may be increased to 100 mg twice daily in severe infections.
Prophylaxis doses
:
Children ≥2 years old: 2.5 mg/kg/dose given once daily (to a maximum initial dose of 200 mg daily). Dose should be adjusted based on therapeutic drug monitoring.
Candidiasis
Non-meningeal Cryptococcosis
Cryptococcal Meningitis
Histoplasmosis

Nausea, abdominal pain, dyspepsia, constipation, headache, dizziness, raised liver enzymes, menstrual disorders, allergic reactions (including pruritus, rash, urticaria and angioedema), hepatitis and cholestatic jaundice, peripheral neuropathy and Stevens-Johnson syndrome reported. On prolonged use hypokalaemia, oedema and hair loss reported.

Itraconazole inhibits Cytochrome P-450 dependent enzymes resulting in impairment of the biosynthesis of ergosterol, a major component of the cell membrane of yeast and fungal cells. Being integral to the proper functioning of the cell membrane, inhibition of the synthesis of ergosterol leads to a cascade of abnormalities in permeability, membrane bound enzyme activity, and co-ordination of chitin synthesis leading to inhibition of growth, abnormal cell wall formation and accumulation of intracellular lipids and membranous vesicles.
SUBA (Super Bio-available) technology is a novel technology for enhancing the bioavailability of poorly soluble drugs. This technology utilizes a solid dispersion of drug in a polymer that improves the dissolution of poorly soluble drugs compared to their normal crystalline form. SUBA technology Itraconazole is an orally active triazole antifungal drug that has demonstrated a broad spectrum of activity and favorable pharmacokinetic profile.